US-based Zumutor Biologics, a Next-Generation Tumor-Directed IO Therapeutics Company leveraging NK cells to modulate the Tumor Micro Environment (TME) to drive transformational change, raised USD 6.2 million on 10th December.
Investors: The investment round was led by new tech investor Siana Capital with Accel and Bharat Innovation Fund (BIF) participation. This brings the total funding to USD 27 million. Furthermore, existing investors Chiratae Ventures, Aarin Capital, and Karnataka Information Technology Venture Capital Fund (KITVEN) participated in the earlier round.
Purpose of funding: The team intends to file an Investigational New Drug Application by the middle of 2022 and start human studies (FIH) in the US by then. Consequently, the startup expects to raise a larger (series B) round after finalizing phase 1 studies and progressing with assets in the pipeline. The startup also plans to set foot in global markets by 2022.
About Zumutor Biologics
Founded in 2015 by Kavitha Iyer Rodrigues, Zumutor Biologics is located in Cambridge, US. Zumutor Biologics is a leading biotechnology startup that provides Next-Generation Tumor-Directed IO Therapeutics Company that uses NK cells to modulate the tumour microenvironment to drive transformational outcomes. The startup has created two antibody engineering platforms to support its discovery and development of immunotherapies (for cancer). It targets the potential to become best-in-class monotherapies and vital elements of innovative combination treatments. Furthermore, this round of funding will enable ZM008 to file for primary approval as a first-in-class asset. A human antibody is designed to activate natural killer (NK) cells and initiate clinical trials in the United States.
What the founder has to say
“Our investors have shown immense trust and gumption in Zumutor’s tech capabilities to take the lead program ZM008, a first-in-class novel monoclonal antibody drug into IND filing and Phase 1 studies,” said Kavitha Iyer Rodrigues, Founder, and CEO at Zumutor Biologics.
“ZM008 – the lead product from the pipeline is a therapeutic antibody aimed to look at solutions for very refractory or “cold” tumour settings where current immunotherapies have had little effect. We aim to address the refractory or “cold” tumours to help convert to immune active or “hot” tumours through a monotherapy/ combination therapy modalities.”
“Zumutor’s aims to look at options of globally licensing the asset on the heels of human data. The other assets in the pipeline are compelling, will also be progressed to preclinical safety. We are in data room diligence with five global biotech/ Biopharmas for licensing.”
For more extensive analysis and Market Intelligence reports feel free to approach us or visit our website: Venture Capital Market Intelligence Reports | VCBay.
We try our best to fact-check and bring the best, well-researched, and non-plagiarized content to you. Please let us know
-if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback and thank you for stopping by!
Next Article
){kind=link}